June 2026 • Prostate cancer is a growing health challenge in India, withover 250,000 cases1 annually and more than half detected atadvanced stages, underscoring the urgent need for earlierdiagnosis and improved access to advanced treatment options. • Radioligand therapy introduces a more targeted treatment approach with the potential to delay disease progression, support overall survival in defined settings, and improve quality of life for patients. • Pluvicto is the country’s first regulatory authority approvedradioligand therapy, marking a significant step forward in precision oncology for advanced prostate cancer. • The launch of Pluvicto reflects Novartis’ continued …

Read More »